Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M <sup>pro</sup> /3CL <sup>pro</sup> in Living Cells
Seyed Arad Moghadasi, Morgan A. Esler, Yuka Otsuka, Jordan T. Becker, Sofia N. Moraes, Constance B. Anderson, Srinivas Chamakuri, Christopher Belica, Chloe Wick, Daniel A. Harki, Damian W. Young, Louis Scampavia, Timothy Spicer, Ke Shi, Hideki Aihara, William L. Brown, Reuben S. Harris
Abstract
variants with altered susceptibilities to inhibition, triage-nonspecific, or off-target molecules and validate bona fide inhibitors, with the most potent thus far being the first-in-class drug nirmatrelvir.
Topics & Concepts
ProteaseLuciferaseProteasesGreen fluorescent proteinComputational biologyProtease inhibitor (pharmacology)Amino acidBiologyViral replicationChemistryBiochemistryCell biologyEnzymeVirologyVirusGeneTransfectionViral loadAntiretroviral therapySARS-CoV-2 and COVID-19 ResearchAdvanced biosensing and bioanalysis techniquesRNA and protein synthesis mechanisms